Five pigs spent six months eating, growing, and swallowing normally — unremarkable, except that a stretch of each animal’s oesophagus had been grown in a laboratory and stitched into place. The engineered tissue developed its own muscles, nerves, and blood vessels. None of the animals needed anti-rejection drugs.

That result, published on 20 March in Nature Biotechnology, represents the first time a lab-grown oesophagus has restored full swallowing function in a large animal. And the researchers behind it already have their next patients in mind: babies born with a gap where their food pipe should be.

A Scaffold, Some Cells, and Two Months

The technique, developed by a team at Great Ormond Street Hospital (GOSH) and University College London, starts with a donor pig oesophagus. Through a process called decellularisation, the tissue is stripped of all its original cells, leaving behind a bare structural scaffold. That scaffold is then seeded with muscle precursor cells and fibroblasts taken from a small biopsy of the recipient pig, multiplied in the lab, and microinjected into the framework.

The repopulated scaffold spends a week in a bioreactor — a container pumping growth fluids through the tissue — before implantation. Start to finish, the process takes roughly two months.

Of eight minipigs that received 2.5-centimetre engineered segments, five survived to the six-month endpoint. The grafts showed full tissue integration within three months, according to lead author Dr Natalie Durkin, a paediatric surgical registrar at GOSH. Because the cells came from the recipients themselves, the grafts were recognised as the animals’ own tissue — eliminating the need for immunosuppression.

The Children Who Need It Most

The clinical target is long-gap oesophageal atresia (LGEA), a birth defect in which the oesophagus is interrupted by a wide gap. Around 180 babies are born with some form of oesophageal atresia each year in the UK alone, and roughly 10% of those have the long-gap variant. Current treatments involve feeding tubes and complex surgeries that reposition sections of stomach or intestine — procedures that carry significant complications.

Dr Marco Pellegrini, a senior researcher at UCL’s Great Ormond Street Institute of Child Health, said the technology could “build a child a new oesophagus, using their own cells” combined with “a ready-prepared scaffold from pig tissue.” Professor Paolo de Coppi, who leads the programme, noted that because the graft uses the patient’s own cells, “it could grow with them over time, without the risk of rejection and without the need for long-term immunosuppression.”

The logistics are surprisingly practical: biopsies could be collected during routine feeding-tube placement, and pre-sized scaffolds could be stored ready for personalisation. The two-month production timeline fits within existing LGEA treatment schedules.

Beyond paediatrics, the technology could serve adults who have lost oesophageal tissue to cancer surgery.

Not Everyone Is Convinced

Prof Dusko Ilic, a stem cell scientist at King’s College London who was not involved in the study, called the work “a significant advance” but cautioned that claims about paediatric suitability are premature. “Normal weight gain should not be interpreted as graft growth,” he said, noting that persistent fibrosis and stricture formation in some animals suggest the construct “behaves as a remodelling scaffold rather than a dynamically growing tissue.”

Three of the eight pigs did not survive to the study’s endpoint — a reminder that the gap between proof-of-concept and clinical reality remains substantial.

The team aims to begin first-in-human research trials within five years, a timeline that will require scaling the graft length, standardising manufacture, and completing safety testing. For the roughly 18 families a year in the UK whose newborns face LGEA, five years is both a long wait and, after more than a decade of work on this technology, the closest the finish line has ever been.

Sources